BIOS.U Stock Overview
BioPlus Acquisition Corp. does not have significant operations. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BioPlus Acquisition Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.80 |
| 52 Week High | US$11.56 |
| 52 Week Low | US$10.06 |
| Beta | 0 |
| 11 Month Change | -0.92% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 7.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOS.U | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | -0.6% | 2.1% | 2.2% |
| 1Y | n/a | 55.8% | 32.6% |
Return vs Industry: Insufficient data to determine how BIOS.U performed against the US Capital Markets industry.
Return vs Market: Insufficient data to determine how BIOS.U performed against the US Market.
Price Volatility
| BIOS.U volatility | |
|---|---|
| BIOS.U Average Weekly Movement | n/a |
| Capital Markets Industry Average Movement | 3.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BIOS.U has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIOS.U's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | R. Ross Haghighat | bioplusspac.com |
BioPlus Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. BioPlus Acquisition Corp. was incorporated in 2021 and is based in New York, New York.
BioPlus Acquisition Corp. Fundamentals Summary
| BIOS.U fundamental statistics | |
|---|---|
| Market cap | US$209.07m |
| Earnings (TTM) | US$5.79m |
| Revenue (TTM) | n/a |
36.1x
P/E Ratio0.0x
P/S RatioIs BIOS.U overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOS.U income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$5.79m |
| Earnings | US$5.79m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -39.6% |
How did BIOS.U perform over the long term?
See historical performance and comparison